Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 5Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Sunitinib 19Everolimus 17Bevacizumab 13aldesleukin 11Sorafenib 11Interleukin-2 10Cyclophosphamide 10Axitinib 10Nivolumab 9fludarabine phosphate 7fludarabine 7pembrolizumab 5Gemcitabine 5temsirolimus 4pazopanib 4Ipilimumab 4peginterferon alfa-2b 3durvalumab 3cabozantinib 3Radiosurgery 3Interferon-alpha 3Granulocyte-Macrophage Colony-Stimulating Factor 3Filgrastim 3Erlotinib Hydrochloride 3Cryosurgery 3vandetanib 2spartalizumab 2perflutren 2ixabepilone 2chiron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Neoplasms × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡